Atrial fibrillation: Recent advances in understanding the role of MicroRNAs in atrial remodeling with an electrophysiological overview

Cardiology (Switzerland)

Volumn 131, Issue 1, 2015, Pages 58-67

  Poudel, Pradeep ^a   Xu, Yanmin ^a   Cui, Zhanqian ^a   Sharma, Deepak ^a   Tian, Bing ^a   Paudel, Sudarshan ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Atrial fibrillation; Atrial remodeling; Electrophysiology; MicroRNAs

Indexed keywords

CALCIUM ION; INWARDLY RECTIFYING POTASSIUM CHANNEL; MICRORNA; MICRORNA 1; MICRORNA 101; MICRORNA 123; MICRORNA 21; MICRORNA 29B; MICRORNA 328; MICRORNA 499; SMALL CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; UNCLASSIFIED DRUG; CALCIUM;

ACTION POTENTIAL DURATION; ATRIAL FIBRILLATION; EXTRASYSTOLE; GENE EXPRESSION; HEART ATRIUM REMODELING; HEART ELECTROPHYSIOLOGY; HUMAN; PRIORITY JOURNAL; REENTRY ARRHYTHMIA; REVIEW; SUPRAVENTRICULAR TACHYCARDIA; UPREGULATION; ANIMAL; ELECTROPHYSIOLOGY; HEART MUSCLE CONDUCTION SYSTEM; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; ATRIAL FIBRILLATION; ATRIAL REMODELING; CALCIUM; ELECTROPHYSIOLOGICAL PHENOMENA; HEART CONDUCTION SYSTEM; HUMANS; MICRORNAS;

EID: 84927949659     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000375403     Document Type: Review

References (72)

1. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS: Secular trends in incidence of atrial fibrillation in Olmsted county, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119-125.
2. Hocini M, Ho SY, Kawara T, Linnenbank AC, Potse M, Shah D, Jais P, Janse MJ, Haissaguerre M, De Bakker JM: Electrical conduction in canine pulmonary veins: electrophysiological and anatomic correlation. Circulation 2002; 105: 2442-2448.
3. Kneller J, Zou R, Vigmond EJ, Wang Z, Leon LJ, Nattel S: Cholinergic atrial fibrillation in a computer model of a two-dimensional sheet of canine atrial cells with realistic ionic properties. Circ Res 2002; 90:E73-E87.
4. Dobrev D, Voigt N, Wehrens XH: The ryanodine receptor channel as a molecular motif in atrial fibrillation: pathophysiological and therapeutic implications. Cardiovasc Res 2011; 89: 734-743.
5. Nattel S, Burstein B, Dobrev D: Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol 2008; 1: 62-73.
6. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB: Prediction of mammalian microRNA targets. Cell 2003; 115: 787-798.
7. Nattel S: New ideas about atrial fibrillation 50 years on. Nature 2002; 415: 219-226.
8. Wakili R, Voigt N, Kaab S, Dobrev D, Nattel S: Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest 2011; 121: 2955-2968.
9. Iwasaki YK, Nishida K, Kato T, Nattel S: Atrial fibrillation pathophysiology: implications for management. Circulation 2011; 124: 2264-2274.
10. De Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen RJ, van den Heijkant AC, Allessie MA, Crijns HJ: Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 2010; 55: 725-731.
11. Nattel S, Maguy A, Le Bouter S, Yeh YH: Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev 2007; 87: 425-456.
12. Katsouras G, Sakabe M, Comtois P, Maguy A, Burstein B, Guerra PG, Talajic M, Nattel S: Differences in atrial fibrillation properties under vagal nerve stimulation versus atrial tachycardia remodeling. Heart Rhythm 2009; 6: 1465-1472.
13. Noujaim SF, Stuckey JA, Ponce-Balbuena D, Ferrer-Villada T, Lopez-Izquierdo A, Pandit S, Calvo CJ, Grzeda KR, Berenfeld O, Chapula JA, Jalife J: Specific residues of the cytoplasmic domains of cardiac inward rectifier potassium channels are effective antifibrillatory targets. FASEB J 2010; 24: 4302-4312.
14. Qi XY, Diness JG, Brundel BJ, Zhou XB, Naud P, Wu CT, Huang H, Harada M, Aflaki M, Dobrev D, Grunnet M, Nattel S: Role of smallconductance calcium-activated potassium channels in atrial electrophysiology and fibrillation in the dog. Circulation 2014; 129: 430-440.
15. Qi XY, Yeh YH, Xiao L, Burstein B, Maguy A, Chartier D, Villeneuve LR, Brundel BJ, Dobrev D, Nattel S: Cellular signaling underlying atrial tachycardia remodeling of L-type calcium current. Circ Res 2008; 103: 845-854.
16. Allessie MA, Boyden PA, Camm AJ, Kleber AG, Lab MJ, Legato MJ, Rosen MR, Schwartz PJ, Spooner PM, Van Wagoner DR, Waldo AL: Pathophysiology and prevention of atrial fibrillation. Circulation 2001; 103: 769-777.
17. Pandit SV, Berenfeld O, Anumonwo JM, Zaritski RM, Kneller J, Nattel S, Jalife J: Ionic determinants of functional reentry in a 2-D model of human atrial cells during simulated chronic atrial fibrillation. Biophys J 2005; 88: 3806-3821.
18. Litchenberg WH, Norman LW, Holwell AK, Martin KL, Hewett KW, Gourdie RG: The rate and anisotropy of impulse propagation in the postnatal terminal crest are correlated with remodeling of Cx43 gap junction pattern. Cardiovasc Res 2000; 45: 379-387.
19. Kostin S, Klein G, Szalay Z, Hein S, Bauer EP, Schaper J: Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 2002; 54: 361-379.
20. Yeh YH, Wakili R, Qi XY, Chartier D, Boknik P, Kaab S, Ravens U, Coutu P, Dobrev D, Nattel S: Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure. Circ Arrhythm Electrophysiol 2008; 1: 93-102.
21. Yue L, Xie J, Nattel S: Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Cardiovasc Res 2011; 89: 744-753.
22. Burstein B, Nattel S: Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008; 51: 802-809.
23. Burstein B, Comtois P, Michael G, Nishida K, Villeneuve L, Yeh YH, Nattel S: Changes in connexin expression and the atrial fibrillation substrate in congestive heart failure. Circ Res 2009; 105: 1213-1222.
24. Xiao HD, Fuchs S, Campbell DJ, Lewis W, Dudley SC Jr, Kasi VS, Hoit BD, Keshelava G, Zhao H, Capecchi MR, Bernstein KE: Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol 2004; 165: 1019-1032.
25. Rosenkranz S: TGF- 1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004; 63: 423-432.
26. Everett TH, Li H, Mangrum JM, McRury ID, Mitchell MA, Redick JA, Haines DE: Electrical, morphological, and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation. Circulation 2000; 102: 1454-1460.
27. Burstein B, Qi XY, Yeh YH, Calderone A, Nattel S: Atrial cardiomyocyte tachycardia alters cardiac fibroblast function: a novel consideration in atrial remodeling. Cardiovasc Res 2007; 76: 442-452.
28. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
29. Vasudevan S, Tong Y, Steitz JA: Switching from repression to activation: microRNAs can up-regulate translation. Science 2007; 318: 1931-1934.
30. Guo H, Ingolia NT, Weissman JS, Bartel DP: Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466: 835-840.
31. Akerman AW, Mukherjee R: MicroRNAs emerging as mediators of remodeling with atrial fibrillation. Heart Rhythm 2013; 10: 1010-1011.
32. Lu Y, Zhang Y, Wang N, Pan Z, Gao X, Zhang F, Zhang Y, Shan H, Luo X, Bai Y, Sun L, Song W, Xu C, Wang Z, Yang B: MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation 2010; 122: 2378-2387.
33. Yang B, Lin H, Xiao J, Lu Y, Luo X, Li B, Zhang Y, Xu C, Bai Y, Wang H, Chen G, Wang Z: The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 2007; 13: 486-491.
34. Luo X, Pan Z, Shan H, Xiao J, Sun X, Wang N, Lin H, Xiao L, Maguy A, Qi XY, Li Y, Gao X, Dong D, Zhang Y, Bai Y, Ai J, Sun L, Lu H, Luo XY, Wang Z, Lu Y, Yang B, Nattel S: MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. J Clin Invest 2013; 123: 1939-1951.
35. Mancarella S, Yue Y, Karnabi E, Qu Y, El-Sherif N, Boutjdir M: Impaired Ca 2+ homeostasis is associated with atrial fibrillation in the alpha1d L-type Ca 2+ channel KO mouse. Am J Physiol Heart Circ Physiol 2008; 295:H2017-H2024.
36. Olesen MS, Jabbari J, Holst AG, Nielsen JB, Steinbruchel DA, Jespersen T, Haunso S, Svendsen JH: Screening of KCNN3 in patients with early-onset lone atrial fibrillation. Europace 2011; 13: 963-967.
37. Ling TY, Wang XL, Chai Q, Lau TW, Koestler CM, Park SJ, Daly RC, Greason KL, Jen J, Wu LQ, Shen WF, Shen WK, Cha YM, Lee HC: Regulation of the SK3 channel by microRNA-499-potential role in atrial fibrillation. Heart Rhythm 2013; 10: 1001-1009.
38. Luo X, Pan Z, Xiao J, Zhang J, Lu Y, Yang B, Wang Z: Electrophysiology TOC: Critical role of microRNAs miR-26 and miR-101 in atrial electrical remodeling in experimental atrial fibrillation. Can J Cardiol 2010; 26: 35D.
39. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliansky V, Rosenwald A, Basson MA, Licht JD, Pena JT, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J, Engelhardt S: MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008; 456: 980-984.
40. Adam O, Lohfelm B, Thum T, Gupta SK, Puhl SL, Schafers HJ, Bohm M, Laufs U: Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res Cardiol 2012; 107: 278.
41. Patrick DM, Montgomery RL, Qi X, Obad S, Kauppinen S, Hill JA, van Rooij E, Olson EN: Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J Clin Invest 2010; 120: 3912-3916.
42. Zhong X, Chung AC, Chen HY, Meng XM, Lan HY: Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J Am Soc Nephrol 2011; 22: 1668-1681.
43. Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Thannickal VJ, Kaminski N, Abraham E: miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 2010; 207: 1589-1597.
44. Cardin S, Guasch E, Luo X, Naud P, Le Quang K, Shi Y, Tardif JC, Comtois P, Nattel S: Role for microRNA-21 in atrial profibrillatory fibrotic remodeling associated with experimental postinfarction heart failure. Circ Arrhythm Electrophysiol 2012; 5: 1027-1035.
45. Nishi H, Sakaguchi T, Miyagawa S, Yoshikawa Y, Fukushima S, Saito S, Ueno T, Kuratani T, Sawa Y: Impact of microRNA expression in human atrial tissue in patients with atrial fibrillation undergoing cardiac surgery. PloS One 2013; 8:e73397.
46. Reilly SN, Jayaram R, Nahar K, Antoniades C, Verheule S, Channon KM, Alp NJ, Schotten U, Casadei B: Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. Circulation 2011; 124: 1107-1117.
47. Liao JK, Laufs U: Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118.
48. Adam O, Frost G, Custodis F, Sussman MA, Schafers HJ, Bohm M, Laufs U: Role of RAC1 GTPase activation in atrial fibrillation. J Am Coll Cardiol 2007; 50: 359-367.
49. Adam O, Theobald K, Lavall D, Grube M, Kroemer HK, Ameling S, Schafers HJ, Bohm M, Laufs U: Increased lysyl oxidase expression and collagen cross-linking during atrial fibrillation. J Mol Cell Cardiol 2011; 50: 678-685.
50. Luo X, Zhang H, Xiao J, Wang Z: Regulation of human cardiac ion channel genes by microRNAs: theoretical perspective and pathophysiological implications. Cell Physiol Biochem 2010; 25: 571-586.
51. Ohanian M, Humphreys DT, Anderson E, Preiss T, Fatkin D: A heterozygous variant in the human cardiac miR-133 gene, miR133a2, alters miRNA duplex processing and strand abundance. BMC Genet 2013; 14: 18.
52. Girmatsion Z, Biliczki P, Bonauer A, Wimmer-Greinecker G, Scherer M, Moritz A, Bukowska A, Goette A, Nattel S, Hohnloser SH, Ehrlich JR: Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation. Heart Rhythm 2009; 6: 1802-1809.
53. Xiao J, Liang D, Zhang Y, Liu Y, Zhang H, Liu Y, Li L, Liang X, Sun Y, Chen YH: MicroRNA expression signature in atrial fibrillation with mitral stenosis. Physiol Genom 2011; 43: 655-664.
54. Cooley N, Cowley MJ, Lin RC, Marasco S, Wong C, Kaye DM, Dart AM, Woodcock EA: Influence of atrial fibrillation on microRNA expression profiles in left and right atria from patients with valvular heart disease. Physiol Genom 2012; 44: 211-219.
55. Li H, Li S, Yu B, Liu S: Expression of miR-133 and miR-30 in chronic atrial fibrillation in canines. Mol Med Rep 2012; 5: 1457-1460.
56. Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, van der Made I, Herias V, van Leeuwen RE, Schellings MW, Barenbrug P, Maessen JG, Heymans S, Pinto YM, Creemers EE: miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 2009; 104: 170-178.
57. Shan H, Zhang Y, Lu Y, Zhang Y, Pan Z, Cai B, Wang N, Li X, Feng T, Hong Y, Yang B: Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines. Cardiovasc Res 2009; 83: 465-472.
58. Castoldi G, Di Gioia CR, Bombardi C, Catalucci D, Corradi B, Gualazzi MG, Leopizzi M, Mancini M, Zerbini G, Condorelli G, Stella A: miR-133a regulates collagen 1a1: potential role of miR-133a in myocardial fibrosis in angiotensin II-dependent hypertension. J Cell Physiol 2012; 227: 850-856.
59. Terentyev D, Belevych AE, Terentyeva R, Martin MM, Malana GE, Kuhn DE, Abdellatif M, Feldman DS, Elton TS, Gyorke S: miR-1 overexpression enhances Ca 2+ release and promotes cardiac arrhythmogenesis by targeting pp2a regulatory subunit B56alpha and causing CAMKII-dependent hyperphosphorylation of RyR2. Circ Res 2009; 104: 514-521.
60. Xu C, Lu Y, Pan Z, Chu W, Luo X, Lin H, Xiao J, Shan H, Wang Z, Yang B: The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci 2007; 120: 3045-3052.
61. Xu GJ, Gan TY, Tang BP, Chen ZH, Ailiman M, Zhou XH, Jiang T, Song JG, Guo X, Li YD, Miao HJ, Zhang Y, Li JX: Changes in microRNAs expression are involved in agerelated atrial structural remodeling and atrial fibrillation. Chin Med J 2013; 126: 1458-1463.
62. Van Rooij E, Sutherland LB, Thatcher JE, Di-Maio JM, Naseem RH, Marshall WS, Hill JA, Olson EN: Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 2008; 105: 13027-13032.
63. Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, Schmidt S, Janssen J, Koppe C, Knolle P, Castoldi M, Tacke F, Trautwein C, Luedde T: Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology (Baltimore, Md) 2011; 53: 209-218.
64. Dawson K, Wakili R, Ordog B, Clauss S, Chen Y, Iwasaki Y, Voigt N, Qi XY, Sinner MF, Dobrev D, Kaab S, Nattel S: MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. Circulation 2013; 127: 1466-1475.
65. Abonnenc M, Nabeebaccus AA, Mayr U, Barallobre-Barreiro J, Dong X, Cuello F, Sur S, Drozdov I, Langley SR, Lu R, Stathopoulou K, Didangelos A, Yin X, Zimmermann WH, Shah AM, Zampetaki A, Mayr M: Extracellular matrix secretion by cardiac fibroblasts: role of microRNA-29b and microRNA-30c. Circ Res 2013; 113: 1138-1147.
66. Hanna N, Cardin S, Leung TK, Nattel S: Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res 2004; 63: 236-244.
67. Mott JL, Kurita S, Cazanave SC, Bronk SF, Werneburg NW, Fernandez-Zapico ME: Transcriptional suppression of miR-29b-1/miR-29a promoter by c-myc, hedgehog, and NF-kappaB. J Cell Biochem 2010; 110: 1155-1164.
68. Qu YC, Du YM, Wu SL, Chen QX, Wu HL, Zhou SF: Activated nuclear factor-kappaB and increased tumor necrosis factor-alpha in atrial tissue of atrial fibrillation. Scand Cardiovasc J 2009; 43: 292-297.
69. Daccarett M, Badger TJ, Akoum N, Burgon NS, Mahnkopf C, Vergara G, Kholmovski E, McGann CJ, Parker D, Brachmann J, Macleod RS, Marrouche NF: Association of left atrial fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation. J Am Coll Cardiol 2011; 57: 831-838.
70. Savelieva I, Kakouros N, Kourliouros A, Camm AJ: Upstream therapies for management of atrial fibrillation: Review of clinical evidence and implications for European Society of Cardiology guidelines. II. Secondary prevention. Europace 2011; 13: 610-625.
71. Nattel S, Dobrev D: The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities. Eur Heart J 2012; 33: 1870-1877.
72. Bikou O, Thomas D, Trappe K, Lugenbiel P, Kelemen K, Koch M, Soucek R, Voss F, Becker R, Katus HA, Bauer A: Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model. Cardiovasc Res 2011; 92: 218-225.